Perfusion Analysis Using Rubidium in Cardiac Sarcoidosis

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT01648933
• Date of registration: 12/04/2012
• Prospective Registration: Yes
• Primary sponsor: Assistance Publique - Hôpitaux de Paris
• Public title: Perfusion Analysis Using Rubidium in Cardiac Sarcoidosis PARCS
• Scientific title: Perfusion Analysis Using Rubidium in Cardiac Sarcoidosis
• Date of first enrolment: July 2012
• Target sample size: 53
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT01648933
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
• Phase: N/A

Countries of recruitment

France

Contacts

• Name: Dominique Le Guludec, MD, PhD
• Affiliation: Assistance Publique - Hôpitaux de Paris

Key inclusion & exclusion criteria

Inclusion Criteria:

- (1) histologically proven sarcoidosis;

- (2) suspicion of cardiac involvement on symptoms, and/or ECG and/or echocardiogram.

Exclusion Criteria:

- patient < 18 years old



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Sarcoidosis

Intervention(s)

Radiation: Rubidium PET

Primary Outcome(s)

percentage of patient who has two different diagnostic and therapeutic attitude before knowing Rubidium-82 PET result and after knowing Rubidium-82 PET result [Time Frame: 60 days]

Secondary Outcome(s)

Analysis of the cost for the use of Sestamibi SPECT and Rb-PET as MPI agents in cardiac sarcoidosis. [Time Frame: 9 months]

Secondary ID(s)

AOR10027

Source(s) of Monetary Support

Please refer to primary and secondary sponsors